With conflict in the Middle East bringing on a global energy market squeeze, one major pharma supplier is raising prices ...
Despite a healthy roster of late-stage assets and a revenue turnaround in 2025, it’s no secret that Biogen has been seeking ...
With a second phase 3 win for Tyvaso in idiopathic pulmonary fibrosis (IPF), United Therapeutics is padding the case for an ...
Insulet has reinstated the chief commercial officer position nearly three years after eliminating the role to pursue more ...
Promotional materials for a handful of biologics have found their way into the FDA’s hot seat. | Promotional materials for a ...
After high-profile moves by Eli Lilly and other Big Pharmas to pause their U.K. | The company is looking to work out an ...
After notching a phase 2 trial win, Idorsia’s insomnia med Quviviq (daridorexant) is one step closer to potentially becoming a first-in-class treatment for children. | After notching a phase 2 trial ...
After Spinraza's FDA approval nearly a decade ago, Biogen's spinal muscular atrophy (SMA) drug captured rapid momentum and delivered blockbuster-level sales in just its second year on the market. | ...
Takeda has started a workforce reduction in the U.S. as the company aims to save more than 200 billion Japanese yen ($1.26 billion) in annual costs. | Takeda has started a workforce reduction in the U ...
High-flying Samsung Biologics is facing a rare bit of public turbulence after the CDMO’s labor union secured the votes needed to strike, signaling a potential escalation in an impasse over what the | ...
With an end-of-week green light from the FDA, Rocket Pharmaceuticals has officially broken into commercial orbit. | Rocket ...
Takeda is launching a restructuring, targeting nearly $1.3 billion in annual savings. Generic versions of Novo Nordisk's ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results